Skip to main content

Advertisement

Table 3 Representative ongoing clinical trials using CTLA-4/PD-1/PD-L1 inhibitors and RT for malignant tumors

From: Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

ClinicalTrials.gov identifier Phase Conditions Drug classification Interventions Sponsors
NCT01996202 Phase 1 Melanoma CTLA-4 inhibitors Ipilimumab with radiation therapy Duke University
NCT02642809 Phase 1 EC PD-1 inhibitors Pembrolizumab with brachytherapy (16 Gy in 2 fractions) Washington University School of Medicine
NCT02837263 Phase 1 Colorectal cancer PD-1 inhibitors Pembrolizumab with SBRT (40–60 Gy in 5 fractions) University of Wisconsin, Madison
NCT02587455 Phase 1 Thoracic tumors PD-1 inhibitors Arm I: pembrolizumab with low-dose radiation therapy
Arm II: pembrolizumab with high-dose radiation therapy
Royal Marsden NHS Foundation Trust
NCT03151447 Phase 1 TNBC PD-L1 inhibitors JS001 with SBRT Fudan University
NCT02868632 Phase 1 Pancreatic cancer PD-L1 and CTLA-4 inhibitors Durvalumab or/and tremelimumab with SBRT (30 Gy in 5 fractions) New York University School of Medicine
NCT03275597 Phase 1 NSCLC PD-L1 and CTLA-4 inhibitors Durvalumab and tremelimumab with SBRT (30–50 Gy in 5 fractions) University of Wisconsin, Madison
NCT02239900 Phase 1/2 Liver cancer, lung cancer CTLA-4 inhibitors Ipilimumab with SBRT M.D. Anderson Cancer Center
NCT03050554 Phase 1/2 NSCLC PD-L1 inhibitors Avelumab with SBRT (48 Gy in 4 fractions or 50 Gy in 5 fractions) Andrew Sharabi
NCT02696993 Phase 1/2 Brain metastases (NSCLC) PD-1 and CTLA-4 inhibitors Arm I: nivolumab with stereotactic radiosurgery
Arm II: nivolumab with whole brain radiation therapy
Arm III: nivolumab and ipilimumab with stereotactic radiosurgeryArm IV: nivolumab and ipilimumab with whole brain radiation therapy
M.D. Anderson Cancer Center
NCT01970527 Phase 2 Melanoma CTLA-4 inhibitors Ipilimumab with SBRT University of Washington
NCT02609503 Phase 2 Head and neck cancer PD-1 inhibitors Pembrolizumab with radiation therapy UNC Lineberger Comprehensive Cancer Center
NCT02730130 Phase 2 Metastatic breast cancer PD-1 inhibitors Pembrolizumab with radiation therapy Memorial Sloan Kettering Cancer Center
NCT02992912 Phase 2 Metastatic tumors PD-L1 inhibitors Atezolizumab with SBRT (45 Gy in 3 fractions) Gustave Roussy, Cancer Campus, Grand Paris
NCT03122509 Phase 2 Metastatic colorectal cancer PD-L1 and CTLA-4 inhibitors Tremelimumab and durvalumab with radiation therapy Memorial Sloan Kettering Cancer Center
NCT02888743 Phase 2 Colorectal cancer and NSCLC PD-L1 and CTLA-4 inhibitors Arm I: tremelimumab and durvalumab
Arm II: tremelimumab and durvalumab with high-dose radiation therapy
Arm III: tremelimumab and durvalumab with low-dose radiation therapy
National Cancer Institute (NCI)
NCT02701400 Phase 2 Recurrent SCLC PD-L1 and CTLA-4 inhibitors Arm I: tremelimumab and durvalumab
Arm II: tremelimumab and durvalumab with SBRT
Emory University
NCT02617589 Phase 3 Brain Cancer PD-1 inhibitors Arm I: nivolumab with radiation therapy
Arm II: temozolomide with radiation therapy
Bristol-Myers Squibb
NCT02768558 Phase 3 NSCLC PD-1 inhibitors Cisplatin and etoposide plus radiation followed by nivolumab RTOG Foundation, Inc.
  1. SCLC small cell lung cancer, NSCLC non-small cell lung cancer, TNBC triple-negative breast cancer, EC esophageal cancer, SBRT stereotactic body radiation therapy